To assess the effect of anti-PD1 treatment (InVivoMAb; BioXCell #BE0273) in combination with SP2509, we performed flow cytometry on 4NQO-induced oral cancer mice. This evidence concerns the gene PDCD1 and lip and oral cavity carcinoma.